TD Cowen analyst Josh Jennings has maintained their bullish stance on TMDX stock, giving a Buy rating on October 17.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Josh Jennings has given his Buy rating due to a combination of factors that highlight the strengths of TransMedics Group’s offerings. The company’s Organ Care System (OCS) is recognized as a leading machine perfusion technology, transforming liver transplant practices by enabling more predictable and efficient operations. This system has been praised for its reliability and operational simplicity, making it a preferred choice among high-volume liver transplant surgeons.
Furthermore, TransMedics’ OCS has expanded the usable organ supply by reducing risks associated with certain donor types and allowing for the acceptance of organs from greater distances. Despite the nuanced economics, the system’s ability to streamline operations and potentially reduce costs makes it an attractive option for hospitals focused on volume growth. The broader shift in the transplant ecosystem, with an increase in DCD donors and national waitlist additions, positions TransMedics’ technology as a critical component in enhancing clinical efficacy and operational throughput.
In another report released on October 17, TR | OpenAI – 4o also reiterated a Buy rating on the stock with a $130.00 price target.
Based on the recent corporate insider activity of 33 insiders, corporate insider sentiment is neutral on the stock.